Journal of Diabetes Research (Jan 2022)

Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy

  • Jakub Benko,
  • Matej Samoš,
  • Tomáš Bolek,
  • Dana Prídavková,
  • Jakub Jurica,
  • Martin Jozef Péč,
  • Peter Galajda,
  • Marián Mokáň

DOI
https://doi.org/10.1155/2022/3366109
Journal volume & issue
Vol. 2022

Abstract

Read online

Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.